PATHFINDER targets the post-discharge gap in heart failure care

Primary care often becomes the long-term home for patients with heart failure with reduced ejection fraction, yet the period after hospital discharge is where treatment momentum frequently stalls. PATHFINDER was designed around that problem. The protocol tests whether a structured, specialist-supported follow-up model can help general practitioners keep patients on track with guideline-directed therapy after an admission for heart failure.

The trial is multicentre and parallel-group, enrolling 200 participants with heart failure with reduced ejection fraction. Recruitment happens during a hospital admission, which is a clinically important choice: this is the moment when patients are already known to have active disease, medication lists are being revised, and the first transition back to community care is about to begin. If medication titration fails at this point, the window for evidence-based optimization can close quickly.

Why the intervention is built around primary care

General practitioners do not lack responsibility in heart failure; they carry much of it. The practical difficulty is execution. Heart failure therapy depends on sequential uptitration, tolerance checks, and repeated medication review, often against a backdrop of older age, multiple comorbidities, blood pressure limits, renal concerns, and competing demands in routine consultations. Even when guidelines are clear, delivery in real-world primary care can lag behind them.

PATHFINDER answers that gap with a deliberately structured intervention. After discharge, participants in the intervention arm will have scheduled GP follow-up at 1 week, 4 weeks, and 3 months. Alongside those visits comes a medication titration plan approved by a specialist heart failure cardiologist. The design does not replace primary care; it equips it with a defined pathway and specialist backing. In a disease where underdosing can leave patients exposed to recurrent decompensation, that support may be the difference between nominal prescribing and truly therapeutic treatment.

What the trial will measure at 6 months

The primary endpoint is clinically grounded and practical: the difference between groups in the proportion of participants prescribed five guideline-recommended treatments at 6 months. Those treatments are: an ACE inhibitor, angiotensin receptor blocker, or angiotensin receptor neprilysin inhibitor at at least 50% of target dose; a beta-blocker at at least 50% of target dose; a mineralocorticoid receptor antagonist at any dose; anticoagulation for patients with atrial fibrillation; and referral to cardiac rehabilitation.

This endpoint reflects how heart failure care is actually judged at the bedside. Medication classes matter, but dose matters too. A patient left on a low dose for months after discharge may be technically treated and still remain undertreated. By requiring at least half of target dose for two core drug classes, the study measures whether the intervention improves the quality of prescribing rather than simply the presence of a prescription.

The inclusion of anticoagulation for atrial fibrillation and referral to cardiac rehabilitation broadens the endpoint beyond pharmacology alone. Heart failure management is never just a pill count. Rhythm-related thromboembolic risk and structured exercise-based recovery both influence function, hospitalization risk, and long-term stability.

The secondary outcomes reflect daily bedside burden

PATHFINDER also reaches beyond prescribing metrics. Secondary outcomes include functional capacity, measured by the 6-minute walk test; quality of life, using the Kansas City Cardiomyopathy Questionnaire; depressive symptoms, assessed with the Patient Health Questionnaire-2; self-care behavior, measured by the Self-Care of Heart Failure Index; and resource utilization.

Those outcomes matter because treatment adherence is not an abstract administrative target. If guideline-directed therapy improves dyspnea, activity tolerance, symptom confidence, and emotional burden, the benefit becomes visible in daily life rather than only on a medication chart. Functional capacity is especially relevant in heart failure, where a modest improvement in exercise tolerance may translate into a meaningful change in independence. Depression and self-care are equally important; patients who understand their condition, monitor symptoms, and respond early to deterioration are more likely to avoid repeat admission.

Resource utilization will also be assessed, giving the trial a broader health-system perspective. A care model that improves medication optimization but generates excessive extra visits, referrals, or downstream service use would be harder to sustain. A lower-burden model that maintains adherence could be easier to scale in routine practice.

The trial tests a workflow, not just a drug

This protocol is notable because it treats heart failure as a systems problem as much as a pharmacologic one. The intervention links hospital discharge to community follow-up with predefined timing and specialist-approved titration guidance. In pathophysiologic terms, the aim is straightforward: sustained neurohormonal blockade and better guideline adherence should reduce the chance that a vulnerable ventricle is left exposed to ongoing maladaptive remodeling.

The model may also reduce the common fragmentation that appears when prescribing responsibility shifts from inpatient teams to primary care. Hospital clinicians often start therapy; community clinicians often inherit it; and dose escalation can drift if no one owns the process. A structured titration plan may close that handoff gap by clarifying what should happen at each visit and when escalation should occur.

One sentence captures the stakes: under-treatment after discharge can become permanent treatment failure.

Ethics, governance, and what remains unproven

Ethical approval came from the South Metropolitan Health Service Ethics Committee, with reciprocal approval at Curtin University. The trial is registered under ACTRN12620001069943, and the planned dissemination route is standard for a clinical study of this type: peer-reviewed publication and conference presentation.

Because this is a protocol, the clinical question remains open. The design is strong in its focus on a real-world transition point, but the results will determine whether specialist-supported primary care follow-up actually changes prescribing behavior, improves patient-centered outcomes, and does so without imposing unsustainable resource demands. The most relevant unknown is not whether guideline-directed therapy is beneficial in heart failure — that is already established — but whether a structured post-discharge pathway can make primary care delivery more consistent for the patients who need it most.


Reporting by Dr. Aishwarya N., MBBS for Medicine World Foundation, with additional data provided by BMJ Open.